Augmedix (AUGX) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

AUGX Stock Forecast


Augmedix stock forecast is as follows: an average price target of $2.67 (represents a 13.62% upside from AUGX’s last price of $2.35) and a rating consensus of 'Hold', based on 5 wall street analysts offering a 1-year stock forecast.

AUGX Price Target


The average price target for Augmedix (AUGX) is $2.67 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $3.50 to $1.50. This represents a potential 13.62% upside from AUGX's last price of $2.35.

AUGX Analyst Ratings


Hold

According to 5 Wall Street analysts, Augmedix's rating consensus is 'Hold'. The analyst rating breakdown for AUGX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 3 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Augmedix Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 14, 2024Brooks O'NeilLoop Capital Markets$3.50$1.15204.35%48.94%
May 14, 2024Yuan ZhiB.Riley Financial$3.00$2.3428.21%27.66%
May 14, 2024Elizabeth AndersonEvercore ISI$1.50$2.34-35.90%-36.17%
Apr 09, 2024Elizabeth AndersonEvercore ISI$5.00$4.0224.38%112.77%
Apr 03, 2024Yuan ZhiB.Riley Financial$5.50$4.0236.82%134.04%
Mar 19, 2024Elizabeth AndersonEvercore ISI$4.50$3.9613.64%91.49%
Row per page
Go to

The latest Augmedix stock forecast, released on May 14, 2024 by Brooks O'Neil from Loop Capital Markets, set a price target of $3.50, which represents a 204.35% increase from the stock price at the time of the forecast ($1.15), and a 48.94% increase from AUGX last price ($2.35).

Augmedix Price Target by Period


1M3M12M
# Anlaysts--6
Avg Price Target--$3.83
Last Closing Price$2.35$2.35$2.35
Upside/Downside-100.00%-100.00%62.98%

In the current month, the average price target of Augmedix stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Augmedix's last price of $2.35. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jul 19, 2024B. Riley-NeutralDowngrade
Jul 19, 2024William Blair-Market PerformDowngrade
Jun 04, 2024Lake StreetBuyBuyHold
May 14, 2024Lake StreetBuyBuyHold
Apr 09, 2024Evercore ISI-OutperformUpgrade
Apr 26, 2022Zacks Investment Research-HoldUpgrade
Row per page
Go to

Augmedix's last stock rating was published by B. Riley on Jul 19, 2024. The company Downgrade its AUGX rating from "null" to "Neutral".

Augmedix Financial Forecast


Augmedix Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
Revenue--------$12.68M$11.77M-$9.63M$8.75M$7.86M$7.33M$6.99M$6.58M$5.63M$5.17M
Avg Forecast$17.70M$16.79M$15.51M$14.59M$12.89M$12.96M$13.64M$13.36M$12.46M$11.43M$10.37M$9.39M$8.57M$7.76M$7.33M$6.91M$6.40M$5.61M$5.18M
High Forecast$17.70M$16.79M$15.51M$14.59M$12.89M$13.07M$13.64M$13.36M$12.46M$11.43M$10.37M$9.39M$8.57M$7.76M$7.33M$6.91M$6.40M$5.61M$5.18M
Low Forecast$17.70M$16.79M$15.51M$14.59M$12.89M$12.83M$13.64M$13.36M$12.46M$11.43M$10.37M$9.39M$8.57M$7.76M$7.33M$6.91M$6.40M$5.61M$5.18M
# Analysts1111121131111111111
Surprise %--------1.02%1.03%-1.03%1.02%1.01%1.00%1.01%1.03%1.00%1.00%

Augmedix's average Quarter revenue forecast for Mar 24 based on 1 analysts is $13.36M, with a low forecast of $13.36M, and a high forecast of $13.36M. AUGX's average Quarter revenue forecast represents a 5.38% increase compared to the company's last Quarter revenue of $12.68M (Dec 23).

Augmedix EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts1111121131111111111
EBITDA--------$-4.04M$-4.40M-$-5.09M$-5.44M$-5.46M$-6.05M$-5.45M$-5.45M$-2.11M$-3.87M
Avg Forecast$-13.30M$-12.62M$-11.65M$-10.96M$-9.68M$-9.74M$-10.25M$-10.04M$-9.36M$-8.59M$-7.79M$-7.06M$-6.44M$-5.83M$-5.51M$-4.28M$-4.81M$-1.90M$-3.89M
High Forecast$-13.30M$-12.62M$-11.65M$-10.96M$-9.68M$-9.64M$-10.25M$-10.04M$-9.36M$-8.59M$-7.79M$-7.06M$-6.44M$-5.83M$-5.51M$-3.43M$-4.81M$-1.52M$-3.89M
Low Forecast$-13.30M$-12.62M$-11.65M$-10.96M$-9.68M$-9.83M$-10.25M$-10.04M$-9.36M$-8.59M$-7.79M$-7.06M$-6.44M$-5.83M$-5.51M$-5.14M$-4.81M$-2.28M$-3.89M
Surprise %--------0.43%0.51%-0.72%0.85%0.94%1.10%1.27%1.13%1.11%0.99%

undefined analysts predict AUGX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Augmedix's previous annual EBITDA (undefined) of $NaN.

Augmedix Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts1111121131111111111
Net Income--------$-4.49M$-4.41M-$-5.27M$-5.76M$-5.52M$-8.84M$-6.43M$-6.08M$-2.86M$-4.64M
Avg Forecast$-4.80M$-5.87M$-6.41M$-6.94M$-7.47M$-7.21M$-7.12M$-6.94M$-5.21M$-6.14M$-6.94M$-8.01M$-8.34M$-9.21M$-8.41M$-5.09M$-8.28M$-2.57M$-10.14M
High Forecast$-4.80M$-5.87M$-6.41M$-6.94M$-7.47M$-7.21M$-7.12M$-6.94M$-5.21M$-6.14M$-6.94M$-8.01M$-8.34M$-9.21M$-8.41M$-4.07M$-8.28M$-2.06M$-10.14M
Low Forecast$-4.80M$-5.87M$-6.41M$-6.94M$-7.47M$-7.21M$-7.12M$-6.94M$-5.21M$-6.14M$-6.94M$-8.01M$-8.34M$-9.21M$-8.41M$-6.11M$-8.28M$-3.09M$-10.14M
Surprise %--------0.86%0.72%-0.66%0.69%0.60%1.05%1.26%0.73%1.11%0.46%

Augmedix's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AUGX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Augmedix SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts1111121131111111111
SG&A--------$7.65M$7.30M-$6.77M$6.88M$6.44M$6.60M$6.28M$-7.92M$5.39M$4.95M
Avg Forecast$15.74M$14.94M$13.79M$12.98M$11.46M$11.52M$12.13M$11.89M$11.08M$10.16M$9.23M$8.35M$7.62M$6.90M$6.52M$5.38M$5.69M$4.86M$4.61M
High Forecast$15.74M$14.94M$13.79M$12.98M$11.46M$11.63M$12.13M$11.89M$11.08M$10.16M$9.23M$8.35M$7.62M$6.90M$6.52M$6.46M$5.69M$5.83M$4.61M
Low Forecast$15.74M$14.94M$13.79M$12.98M$11.46M$11.41M$12.13M$11.89M$11.08M$10.16M$9.23M$8.35M$7.62M$6.90M$6.52M$4.30M$5.69M$3.88M$4.61M
Surprise %--------0.69%0.72%-0.81%0.90%0.93%1.01%1.17%-1.39%1.11%1.07%

Augmedix's average Quarter SG&A projection for Mar 24 is $11.89M, based on 1 Wall Street analysts, with a range of $11.89M to $11.89M. The forecast indicates a 55.30% rise compared to AUGX last annual SG&A of $7.65M (Dec 23).

Augmedix EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21
# Analysts1111121131111111111
EPS--------$-0.09$-0.10-$-0.14$-0.15$-0.15$-0.24$-0.17$-0.16$-0.11$-0.17
Avg Forecast$-0.09$-0.11$-0.12$-0.13$-0.14$-0.14$-0.13$-0.13$-0.10$-0.12$-0.13$-0.15$-0.16$-0.17$-0.16$-0.15$-0.15$-0.14$-0.19
High Forecast$-0.09$-0.11$-0.12$-0.13$-0.14$-0.14$-0.13$-0.13$-0.10$-0.12$-0.13$-0.15$-0.16$-0.17$-0.16$-0.15$-0.15$-0.14$-0.19
Low Forecast$-0.09$-0.11$-0.12$-0.13$-0.14$-0.14$-0.13$-0.13$-0.10$-0.12$-0.13$-0.15$-0.16$-0.17$-0.16$-0.15$-0.15$-0.14$-0.19
Surprise %--------0.94%0.84%-0.93%0.96%0.87%1.52%1.11%1.03%0.76%0.89%

According to undefined Wall Street analysts, Augmedix's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AUGX previous annual EPS of $NaN (undefined).

Augmedix Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
UTRSMinerva Surgical$0.01$5.0049900.00%Buy
INABIN8bio$0.30$14.004566.67%Buy
ELEVElevation Oncology$0.52$9.001630.77%Buy
DRMADermata Therapeutics$1.22$6.00391.80%Buy
AUGXAugmedix$2.35$2.6713.62%Hold

AUGX Forecast FAQ


No, according to 5 Wall Street analysts, Augmedix (AUGX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 40.00% of AUGX's total ratings.

Augmedix (AUGX) average price target is $2.67 with a range of $1.5 to $3.5, implying a 13.62% from its last price of $2.35. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for AUGX stock, the company can go up by 13.62% (from the last price of $2.35 to the average price target of $2.67), up by 48.94% based on the highest stock price target, and down by -36.17% based on the lowest stock price target.

AUGX's average twelve months analyst stock price target of $2.67 does not support the claim that Augmedix can reach $4 in the near future.

Augmedix's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $52.84M (high $52.96M, low $52.71M), average EBITDA is $-39.708M (high $-39.612M, low $-39.797M), average net income is $-28.74M (high $-28.74M, low $-28.74M), average SG&A $47M (high $47.11M, low $46.89M), and average EPS is $-0.538 (high $-0.538, low $-0.538). AUGX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $64.59M (high $64.59M, low $64.59M), average EBITDA is $-48.538M (high $-48.538M, low $-48.538M), average net income is $-24.024M (high $-24.024M, low $-24.024M), average SG&A $57.45M (high $57.45M, low $57.45M), and average EPS is $-0.45 (high $-0.45, low $-0.45).

Based on Augmedix's last annual report (Dec 2023), the company's revenue was $44.86M, beating the average analysts forecast of $43.65M by 2.76%. Apple's EBITDA was $-17.681M, missing the average prediction of $-32.803M by -46.10%. The company's net income was $-19.171M, missing the average estimation of $-26.293M by -27.09%. Apple's SG&A was $29.13M, missing the average forecast of $38.83M by -24.98%. Lastly, the company's EPS was $-0.44, missing the average prediction of $-0.493 by -10.66%. In terms of the last quarterly report (Dec 2023), Augmedix's revenue was $12.68M, beating the average analysts' forecast of $12.46M by 1.77%. The company's EBITDA was $-4.041M, missing the average prediction of $-9.363M by -56.84%. Augmedix's net income was $-4.491M, missing the average estimation of $-5.205M by -13.72%. The company's SG&A was $7.65M, missing the average forecast of $11.08M by -30.95%. Lastly, the company's EPS was $-0.0916, missing the average prediction of $-0.0975 by -6.05%